Herceptin aces stomach-cancer trial

On the "good news" side of Roche's ledger today, the company announced results of a big study that shows Herceptin significantly prolongs the life of stomach cancer patients when added to standard chemotherapy. It's the second chunk of positive data for Herceptin in 10 days; last week, a study showed the drug benefits HER2-positive breast cancer patients for several years after treatment is concluded.

In the international stomach-cancer trial, known as ToGA, Herceptin "significantly" prolonged the lives of patients with HER2-positive, advanced stomach cancer. "This is definitely good news," Helvea analyst Karl-Heinz Koch told Dow Jones. And according to Roche's pharma CEO Bill Burns, "The ToGA study shows for the first time that Herceptin extends the lives of patients in a cancer other than breast cancer."

About 900,000 new cases of stomach cancer are diagnosed each year, with 22 percent of stomach tumors deemed HER2-positive.

Developed by Genentech--which, as you know, just agreed to a merger with Roche--Herceptin is marketed in Japan by Chugai Pharmaceuticals, internationally by Roche, and in the U.S. by Genentech. 

- check out the release from Roche
- see the Dow Jones article

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.